---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065191"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:09.064708+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beam Q4 net income $244.3M (full-year loss $80.0M); new PKU program; $500M Sixth Street credit facility

## Summary
- Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).
- New liver-targeted program BEAM-304 for PKU; IND filing expected in 2026; targets two most prevalent PAH mutations.
- $500M senior secured credit facility with Sixth Street; $100M funded at close; additional draws tied to risto-cel milestones.
- Cash, cash equivalents and marketable securities $1.25B as of Dec 31, 2025; runway into mid-2029 with Sixth Street capital.
- Risto-cel BLA submission expected as early as year-end 2026; BEAM-302 FDA alignment on accelerated approval path.

## SEC filing metadata
- accession: 0001193125-26-065191
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/0001193125-26-065191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065191
- JSON: https://secwatch.observer/filing/0001193125-26-065191.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065191.txt

## Source-grounded claims
- claim_id: 763083ed11606e367a4c105756e3e849dc25a541
  claim: Beam Therapeutics Inc. incurred term loan of up to $500 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% f maturing February 24, 2033.
  evidence_excerpt: On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $500 million (the “Credit Facility”), consisting of (i) an initial draw of $100 million on the Closing Date,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/0001193125-26-065191-index.htm
- claim_id: 574add84a2a6aeb258a3ec8ce516e9ca8e1bf697
  claim: Beam Therapeutics Inc. entered into Financing Agreement with Sixth Street Lending Partners, as administrative agent and collateral agent valued at $500 million (effective 2026-02-24).
  evidence_excerpt: On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/0001193125-26-065191-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.